Xcout IntelCalidi Biotherapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Calidi Biotherapeutics, Inc. among biotech companies — ranked by similarity to what Calidi Biotherapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Calidi Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Calidi Biotherapeutics, Inc. at a glance
Calidi Biotherapeutics, Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (CLDI) with a market capitalisation of $755,117. Xcout tracks 19 named people at Calidi Biotherapeutics, Inc., including Eric E. Poma (Chief Executive Officer & Director).
Calidi Biotherapeutics, Inc. leadership
- Eric E. PomaChief Executive Officer & Director
- Eric Poma, Ph.D.Chief Executive Officer and Director
- Andrew C. JacksonChief Financial Officer & Corporate Secretary
- Andrew JacksonChief Financial Officer
- Antonio F. Santidrian, PharmD, Ph.D.Chief Scientific Officer and Head of Technical Operations
- Antonio Fernandez SantidrianHead of Technical Operations & Chief Scientific Officer
13 more named people on record for Calidi Biotherapeutics, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Calidi Biotherapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Calidi Biotherapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
IconOVir Bio, Inc. is a preclinical-stage biotechnology company headquartered in New York, United States, with a primary location in San Diego, California. Established in 2020, the venture-backed company is dedicated to pioneering novel oncolytic viral therapies to cure cancer and restore life to patients.
Biotechnology
CVBio is a biotechnology company that develops virus-driven immunotherapies, specifically utilizing engineered oncolytic adenoviruses to target and destroy resistant cancer cells. The company's platform is designed to treat aggressive cancers, including adult and pediatric brain tumors, by selectively infecting tumor cells and eliciting an anti-tumor immune response.
Biotechnology
Kadimastem Ltd. is a clinical-stage cell therapy company headquartered in Ness Ziona, Israel, focused on developing advanced cell-based therapeutic treatments.
Similar biotech company
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Biotechnology
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
Biotechnology
BioEclipse Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in California. The company is focused on researching and developing a novel generation of targeted immunotherapies and treatments for oncology.
Similar biotech company
Neuvogen is a privately held immunooncology company headquartered in San Diego, California, applying a systems approach to develop advanced therapies. The organization operates with a small team focused on cancer immunotherapy solutions.
Similar biotech company
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Biotechnology
Altido Therapeutics is a clinical-stage biotechnology company located in Waltham, Massachusetts that is advancing a dual-mechanism CAR-TEAM immunotherapy platform to treat glioblastoma.
Biotechnology
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Biotechnology
Hookipa Pharma Inc. is a clinical-stage biotechnology company developing immunotherapies and vaccines based on arenavirus vectors, designed to stimulate targeted T-cell and antibody responses. Its programs have focused on cancer and infectious diseases, serving patients through potential therapeutic and preventive treatments.
Similar biotech company
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Calidi Biotherapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Calidi Biotherapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →